[go: up one dir, main page]

WO2001015736A3 - Interferon-beta conjugates - Google Patents

Interferon-beta conjugates Download PDF

Info

Publication number
WO2001015736A3
WO2001015736A3 PCT/DK2000/000471 DK0000471W WO0115736A3 WO 2001015736 A3 WO2001015736 A3 WO 2001015736A3 DK 0000471 W DK0000471 W DK 0000471W WO 0115736 A3 WO0115736 A3 WO 0115736A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
polypeptide
amino acid
moiety
polypeptide moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2000/000471
Other languages
French (fr)
Other versions
WO2001015736A2 (en
Inventor
Anders Hjelholt Pedersen
Hans Thalsgaard Schambye
Kim Vilbour Andersen
Claus Bornaes
Poul Baad Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Original Assignee
Maxygen ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00954404A priority Critical patent/EP1328295A2/en
Priority to AU66870/00A priority patent/AU6687000A/en
Priority to BR0013638-7A priority patent/BR0013638A/en
Priority to HU0302674A priority patent/HUP0302674A2/en
Priority to MXPA02001969A priority patent/MXPA02001969A/en
Priority to IL14758100A priority patent/IL147581A0/en
Priority to CA002380760A priority patent/CA2380760A1/en
Priority to SK294-2002A priority patent/SK2942002A3/en
Priority to JP2001520147A priority patent/JP2003527090A/en
Application filed by Maxygen ApS filed Critical Maxygen ApS
Priority to KR1020027002608A priority patent/KR20020034181A/en
Publication of WO2001015736A2 publication Critical patent/WO2001015736A2/en
Priority to AU42310/01A priority patent/AU4231001A/en
Priority to PCT/DK2001/000182 priority patent/WO2001068141A2/en
Priority to NO20020929A priority patent/NO20020929L/en
Anticipated expiration legal-status Critical
Publication of WO2001015736A3 publication Critical patent/WO2001015736A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A conjugate exhibiting interferon β activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon β polypeptide, the amino acid sequence of which differs from that of wildtype human interferon β in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy.
PCT/DK2000/000471 1999-08-27 2000-08-25 Interferon-beta conjugates Ceased WO2001015736A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2001520147A JP2003527090A (en) 1999-08-27 2000-08-25 Novel interferon beta-like molecule
BR0013638-7A BR0013638A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
HU0302674A HUP0302674A2 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
MXPA02001969A MXPA02001969A (en) 1999-08-27 2000-08-25 New interferon betalike molecules.
IL14758100A IL147581A0 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
CA002380760A CA2380760A1 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
SK294-2002A SK2942002A3 (en) 1999-08-27 2000-08-25 A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
EP00954404A EP1328295A2 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
KR1020027002608A KR20020034181A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
AU66870/00A AU6687000A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
AU42310/01A AU4231001A (en) 2000-03-17 2001-03-16 Dispersions of polypeptide conjugates
PCT/DK2001/000182 WO2001068141A2 (en) 2000-03-17 2001-03-16 Dispersions of polypeptide conjugates
NO20020929A NO20020929L (en) 1999-08-27 2002-02-26 Novel interferon beta-like molecules

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DKPA199901197 1999-08-27
DKPA199901197 1999-08-27
US16078299P 1999-10-21 1999-10-21
US60/160,782 1999-10-21
DKPA199901691 1999-11-26
DKPA199901691 1999-11-26
DKPA200000194 2000-02-07
DKPA200000194 2000-02-07
DKPA200000363 2000-03-07
DKPA200000363 2000-03-07
DKPA200000642 2000-04-14
DKPA200000642 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001015736A2 WO2001015736A2 (en) 2001-03-08
WO2001015736A3 true WO2001015736A3 (en) 2003-05-22

Family

ID=27545189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000471 Ceased WO2001015736A2 (en) 1999-08-27 2000-08-25 Interferon-beta conjugates

Country Status (14)

Country Link
EP (1) EP1328295A2 (en)
JP (1) JP2003527090A (en)
KR (1) KR20020034181A (en)
CN (1) CN1501815A (en)
AU (1) AU6687000A (en)
BR (1) BR0013638A (en)
CA (1) CA2380760A1 (en)
CZ (1) CZ2002521A3 (en)
HU (1) HUP0302674A2 (en)
IL (1) IL147581A0 (en)
MX (1) MXPA02001969A (en)
NO (1) NO20020929L (en)
SK (1) SK2942002A3 (en)
WO (1) WO2001015736A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104043112B (en) * 2014-07-01 2016-03-30 哈药集团生物工程有限公司 A kind of ointment pharmaceutical composition containing recombinanthumaninterferonα-2b (pseudomonas)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762616B2 (en) * 1998-10-16 2003-07-03 Biogen Ma Inc. Polymer conjugates of interferon beta-1a and uses
ES2265693T3 (en) 1998-10-16 2007-02-16 Biogen Idec Ma Inc. FUSION PROTEINS WITH INTERFERON-BETA AND USES.
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
EP1334128A2 (en) * 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
JP2004534523A (en) 2001-02-27 2004-11-18 マキシゲン・エイピーエス Novel interferon beta-like molecule
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
KR100511749B1 (en) * 2001-11-06 2005-09-02 선바이오(주) Modified interferon-beta, and chemically modified conjugates thereof
MXPA04006855A (en) 2002-01-18 2005-04-19 Biogen Idec Inc Polyalkylene polymer compounds and uses thereof.
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
WO2004060299A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
EP1666496B1 (en) 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP2059528A2 (en) * 2006-08-08 2009-05-20 Novartis Ag Recombinant interferon-beta with enhanced biological activity
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
SI3215193T1 (en) 2014-11-06 2024-02-29 Pharmaessentia Corporation Dosage regimen for pegylated interferon
EP3454887B1 (en) * 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
WO1995027502A1 (en) * 1994-04-12 1995-10-19 Research Development Foundation Method of treating auto-immune diseases using type one interferons
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1998035026A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2000023114A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Polymer conjugates of interferon beta- 1a and their uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3676670D1 (en) * 1985-06-26 1991-02-07 Cetus Corp SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1995027502A1 (en) * 1994-04-12 1995-10-19 Research Development Foundation Method of treating auto-immune diseases using type one interferons
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1998035026A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2000023114A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Polymer conjugates of interferon beta- 1a and their uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104043112B (en) * 2014-07-01 2016-03-30 哈药集团生物工程有限公司 A kind of ointment pharmaceutical composition containing recombinanthumaninterferonα-2b (pseudomonas)

Also Published As

Publication number Publication date
IL147581A0 (en) 2002-08-14
WO2001015736A2 (en) 2001-03-08
NO20020929D0 (en) 2002-02-26
CZ2002521A3 (en) 2002-05-15
NO20020929L (en) 2002-04-25
EP1328295A2 (en) 2003-07-23
CA2380760A1 (en) 2001-03-08
BR0013638A (en) 2002-05-14
SK2942002A3 (en) 2002-08-06
JP2003527090A (en) 2003-09-16
AU6687000A (en) 2001-03-26
CN1501815A (en) 2004-06-02
KR20020034181A (en) 2002-05-08
HUP0302674A2 (en) 2003-11-28
MXPA02001969A (en) 2003-07-21

Similar Documents

Publication Publication Date Title
WO2001036001A3 (en) Interferon gamma conjugates
WO2001015736A3 (en) Interferon-beta conjugates
WO2002074806A3 (en) New interferon beta-like molecules
WO2001051510A3 (en) G-csf conjugates
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
EP2112161A3 (en) Peptides that lower blood glucose levels
CA2063886A1 (en) Polyethylene protein conjugates
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
WO1997025052A3 (en) Compositions comprising pvp having an average molecular weight in the range of 3,000 to 14,000 daltons
EP2186902A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
BRPI9809791B8 (en) aminoalkyl glucosamine phosphate immuno-effecting compounds and compositions comprising the same
CA2064689A1 (en) Stabilized protein or peptide conjugates
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
EP2266590A3 (en) Active agent delivery sytems and methods for protecting and administering active agents
AU6934300A (en) Tissue electroperforation for drug delivery and diagnostic sampling
WO2001058493A8 (en) Conjugates of follicle stimulating hormones
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
EP2213302A3 (en) DR4 antibodies and uses thereof
WO2003055916A3 (en) Adiponectin fragments and conjugates
WO1996003502A3 (en) Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
YU32402A (en) Interferon gamma conjugates
UA100967C2 (en) Normal;heading 1;heading 2;heading 3;POLYMER CONJUGATES OF NEUBLASTIN AND METHODS OF USING SAME
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 147581

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/00337

Country of ref document: ZA

Ref document number: 200200337

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000954404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2380760

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 66870/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2002-521

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/256/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001969

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2942002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020027002608

Country of ref document: KR

Ref document number: 008121966

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2002 2002107676

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027002608

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-521

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000954404

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-521

Country of ref document: CZ